Neisseria meningitidis Infections Drug-Asia Pacific Market Status and Trend Report 2013-2023
Report Summary
Neisseria meningitidis Infections Drug-Asia Pacific Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Neisseria meningitidis Infections Drug industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Asia Pacific and Regional Market Size of Neisseria meningitidis Infections Drug 2013-2017, and development forecast 2018-2023
Main market players of Neisseria meningitidis Infections Drug in Asia Pacific, with company and product introduction, position in the Neisseria meningitidis Infections Drug market
Market status and development trend of Neisseria meningitidis Infections Drug by types and applications
Cost and profit status of Neisseria meningitidis Infections Drug, and marketing status
Market growth drivers and challenges
The report segments the Asia Pacific Neisseria meningitidis Infections Drug market as:
Asia Pacific Neisseria meningitidis Infections Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
China
Japan
Korea
India
Southeast Asia
Australia
Asia Pacific Neisseria meningitidis Infections Drug Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
MGBBP-3
NCL-195
TP-10
Others
Asia Pacific Neisseria meningitidis Infections Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Clinic
Others
Asia Pacific Neisseria meningitidis Infections Drug Market: Players Segment Analysis (Company and Product introduction, Neisseria meningitidis Infections Drug Sales Volume, Revenue, Price and Gross Margin):
Beijing Minhai Biotechnology Co Ltd
Biological E Ltd
China National Pharmaceutical Group Corp
GlaxoSmithKline Plc
Griffith University
ImmunoBiology Ltd
JN-International Medical Corp
MGB Biopharma Ltd
Panacea Biotec Ltd
Pfizer Inc
Sanofi Pasteur SA
Serum Institute of India Ltd
Wellstat Vaccines LLC
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Neisseria meningitidis Infections Drug-Asia Pacific Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Neisseria meningitidis Infections Drug industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Asia Pacific and Regional Market Size of Neisseria meningitidis Infections Drug 2013-2017, and development forecast 2018-2023
Main market players of Neisseria meningitidis Infections Drug in Asia Pacific, with company and product introduction, position in the Neisseria meningitidis Infections Drug market
Market status and development trend of Neisseria meningitidis Infections Drug by types and applications
Cost and profit status of Neisseria meningitidis Infections Drug, and marketing status
Market growth drivers and challenges
The report segments the Asia Pacific Neisseria meningitidis Infections Drug market as:
Asia Pacific Neisseria meningitidis Infections Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
China
Japan
Korea
India
Southeast Asia
Australia
Asia Pacific Neisseria meningitidis Infections Drug Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
MGBBP-3
NCL-195
TP-10
Others
Asia Pacific Neisseria meningitidis Infections Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Clinic
Others
Asia Pacific Neisseria meningitidis Infections Drug Market: Players Segment Analysis (Company and Product introduction, Neisseria meningitidis Infections Drug Sales Volume, Revenue, Price and Gross Margin):
Beijing Minhai Biotechnology Co Ltd
Biological E Ltd
China National Pharmaceutical Group Corp
GlaxoSmithKline Plc
Griffith University
ImmunoBiology Ltd
JN-International Medical Corp
MGB Biopharma Ltd
Panacea Biotec Ltd
Pfizer Inc
Sanofi Pasteur SA
Serum Institute of India Ltd
Wellstat Vaccines LLC
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF NEISSERIA MENINGITIDIS INFECTIONS DRUG
1.1 Definition of Neisseria meningitidis Infections Drug in This Report
1.2 Commercial Types of Neisseria meningitidis Infections Drug
1.2.1 MGBBP-3
1.2.2 NCL-195
1.2.3 TP-10
1.2.4 Others
1.3 Downstream Application of Neisseria meningitidis Infections Drug
1.3.1 Hospital
1.3.2 Clinic
1.3.3 Others
1.4 Development History of Neisseria meningitidis Infections Drug
1.5 Market Status and Trend of Neisseria meningitidis Infections Drug 2013-2023
1.5.1 Asia Pacific Neisseria meningitidis Infections Drug Market Status and Trend 2013-2023
1.5.2 Regional Neisseria meningitidis Infections Drug Market Status and Trend 2013-2023
CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Neisseria meningitidis Infections Drug in Asia Pacific 2013-2017
2.2 Consumption Market of Neisseria meningitidis Infections Drug in Asia Pacific by Regions
2.2.1 Consumption Volume of Neisseria meningitidis Infections Drug in Asia Pacific by Regions
2.2.2 Revenue of Neisseria meningitidis Infections Drug in Asia Pacific by Regions
2.3 Market Analysis of Neisseria meningitidis Infections Drug in Asia Pacific by Regions
2.3.1 Market Analysis of Neisseria meningitidis Infections Drug in China 2013-2017
2.3.2 Market Analysis of Neisseria meningitidis Infections Drug in Japan 2013-2017
2.3.3 Market Analysis of Neisseria meningitidis Infections Drug in Korea 2013-2017
2.3.4 Market Analysis of Neisseria meningitidis Infections Drug in India 2013-2017
2.3.5 Market Analysis of Neisseria meningitidis Infections Drug in Southeast Asia 2013-2017
2.3.6 Market Analysis of Neisseria meningitidis Infections Drug in Australia 2013-2017
2.4 Market Development Forecast of Neisseria meningitidis Infections Drug in Asia Pacific 2018-2023
2.4.1 Market Development Forecast of Neisseria meningitidis Infections Drug in Asia Pacific 2018-2023
2.4.2 Market Development Forecast of Neisseria meningitidis Infections Drug by Regions 2018-2023
CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Asia Pacific Market Status by Types
3.1.1 Consumption Volume of Neisseria meningitidis Infections Drug in Asia Pacific by Types
3.1.2 Revenue of Neisseria meningitidis Infections Drug in Asia Pacific by Types
3.2 Asia Pacific Market Status by Types in Major Countries
3.2.1 Market Status by Types in China
3.2.2 Market Status by Types in Japan
3.2.3 Market Status by Types in Korea
3.2.4 Market Status by Types in India
3.2.5 Market Status by Types in Southeast Asia
3.2.6 Market Status by Types in Australia
3.3 Market Forecast of Neisseria meningitidis Infections Drug in Asia Pacific by Types
CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Neisseria meningitidis Infections Drug in Asia Pacific by Downstream Industry
4.2 Demand Volume of Neisseria meningitidis Infections Drug by Downstream Industry in Major Countries
4.2.1 Demand Volume of Neisseria meningitidis Infections Drug by Downstream Industry in China
4.2.2 Demand Volume of Neisseria meningitidis Infections Drug by Downstream Industry in Japan
4.2.3 Demand Volume of Neisseria meningitidis Infections Drug by Downstream Industry in Korea
4.2.4 Demand Volume of Neisseria meningitidis Infections Drug by Downstream Industry in India
4.2.5 Demand Volume of Neisseria meningitidis Infections Drug by Downstream Industry in Southeast Asia
4.2.6 Demand Volume of Neisseria meningitidis Infections Drug by Downstream Industry in Australia
4.3 Market Forecast of Neisseria meningitidis Infections Drug in Asia Pacific by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF NEISSERIA MENINGITIDIS INFECTIONS DRUG
5.1 Asia Pacific Economy Situation and Trend Overview
5.2 Neisseria meningitidis Infections Drug Downstream Industry Situation and Trend Overview
CHAPTER 6 NEISSERIA MENINGITIDIS INFECTIONS DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC
6.1 Sales Volume of Neisseria meningitidis Infections Drug in Asia Pacific by Major Players
6.2 Revenue of Neisseria meningitidis Infections Drug in Asia Pacific by Major Players
6.3 Basic Information of Neisseria meningitidis Infections Drug by Major Players
6.3.1 Headquarters Location and Established Time of Neisseria meningitidis Infections Drug Major Players
6.3.2 Employees and Revenue Level of Neisseria meningitidis Infections Drug Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 NEISSERIA MENINGITIDIS INFECTIONS DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Beijing Minhai Biotechnology Co Ltd
7.1.1 Company profile
7.1.2 Representative Neisseria meningitidis Infections Drug Product
7.1.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of Beijing Minhai Biotechnology Co Ltd
7.2 Biological E Ltd
7.2.1 Company profile
7.2.2 Representative Neisseria meningitidis Infections Drug Product
7.2.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of Biological E Ltd
7.3 China National Pharmaceutical Group Corp
7.3.1 Company profile
7.3.2 Representative Neisseria meningitidis Infections Drug Product
7.3.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of China National Pharmaceutical Group Corp
7.4 GlaxoSmithKline Plc
7.4.1 Company profile
7.4.2 Representative Neisseria meningitidis Infections Drug Product
7.4.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of GlaxoSmithKline Plc
7.5 Griffith University
7.5.1 Company profile
7.5.2 Representative Neisseria meningitidis Infections Drug Product
7.5.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of Griffith University
7.6 ImmunoBiology Ltd
7.6.1 Company profile
7.6.2 Representative Neisseria meningitidis Infections Drug Product
7.6.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of ImmunoBiology Ltd
7.7 JN-International Medical Corp
7.7.1 Company profile
7.7.2 Representative Neisseria meningitidis Infections Drug Product
7.7.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of JN-International Medical Corp
7.8 MGB Biopharma Ltd
7.8.1 Company profile
7.8.2 Representative Neisseria meningitidis Infections Drug Product
7.8.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of MGB Biopharma Ltd
7.9 Panacea Biotec Ltd
7.9.1 Company profile
7.9.2 Representative Neisseria meningitidis Infections Drug Product
7.9.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of Panacea Biotec Ltd
7.10 Pfizer Inc
7.10.1 Company profile
7.10.2 Representative Neisseria meningitidis Infections Drug Product
7.10.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of Pfizer Inc
7.11 Sanofi Pasteur SA
7.11.1 Company profile
7.11.2 Representative Neisseria meningitidis Infections Drug Product
7.11.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of Sanofi Pasteur SA
7.12 Serum Institute of India Ltd
7.12.1 Company profile
7.12.2 Representative Neisseria meningitidis Infections Drug Product
7.12.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of Serum Institute of India Ltd
7.13 Wellstat Vaccines LLC
7.13.1 Company profile
7.13.2 Representative Neisseria meningitidis Infections Drug Product
7.13.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of Wellstat Vaccines LLC
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NEISSERIA MENINGITIDIS INFECTIONS DRUG
8.1 Industry Chain of Neisseria meningitidis Infections Drug
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF NEISSERIA MENINGITIDIS INFECTIONS DRUG
9.1 Cost Structure Analysis of Neisseria meningitidis Infections Drug
9.2 Raw Materials Cost Analysis of Neisseria meningitidis Infections Drug
9.3 Labor Cost Analysis of Neisseria meningitidis Infections Drug
9.4 Manufacturing Expenses Analysis of Neisseria meningitidis Infections Drug
CHAPTER 10 MARKETING STATUS ANALYSIS OF NEISSERIA MENINGITIDIS INFECTIONS DRUG
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Neisseria meningitidis Infections Drug in This Report
1.2 Commercial Types of Neisseria meningitidis Infections Drug
1.2.1 MGBBP-3
1.2.2 NCL-195
1.2.3 TP-10
1.2.4 Others
1.3 Downstream Application of Neisseria meningitidis Infections Drug
1.3.1 Hospital
1.3.2 Clinic
1.3.3 Others
1.4 Development History of Neisseria meningitidis Infections Drug
1.5 Market Status and Trend of Neisseria meningitidis Infections Drug 2013-2023
1.5.1 Asia Pacific Neisseria meningitidis Infections Drug Market Status and Trend 2013-2023
1.5.2 Regional Neisseria meningitidis Infections Drug Market Status and Trend 2013-2023
CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Neisseria meningitidis Infections Drug in Asia Pacific 2013-2017
2.2 Consumption Market of Neisseria meningitidis Infections Drug in Asia Pacific by Regions
2.2.1 Consumption Volume of Neisseria meningitidis Infections Drug in Asia Pacific by Regions
2.2.2 Revenue of Neisseria meningitidis Infections Drug in Asia Pacific by Regions
2.3 Market Analysis of Neisseria meningitidis Infections Drug in Asia Pacific by Regions
2.3.1 Market Analysis of Neisseria meningitidis Infections Drug in China 2013-2017
2.3.2 Market Analysis of Neisseria meningitidis Infections Drug in Japan 2013-2017
2.3.3 Market Analysis of Neisseria meningitidis Infections Drug in Korea 2013-2017
2.3.4 Market Analysis of Neisseria meningitidis Infections Drug in India 2013-2017
2.3.5 Market Analysis of Neisseria meningitidis Infections Drug in Southeast Asia 2013-2017
2.3.6 Market Analysis of Neisseria meningitidis Infections Drug in Australia 2013-2017
2.4 Market Development Forecast of Neisseria meningitidis Infections Drug in Asia Pacific 2018-2023
2.4.1 Market Development Forecast of Neisseria meningitidis Infections Drug in Asia Pacific 2018-2023
2.4.2 Market Development Forecast of Neisseria meningitidis Infections Drug by Regions 2018-2023
CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Asia Pacific Market Status by Types
3.1.1 Consumption Volume of Neisseria meningitidis Infections Drug in Asia Pacific by Types
3.1.2 Revenue of Neisseria meningitidis Infections Drug in Asia Pacific by Types
3.2 Asia Pacific Market Status by Types in Major Countries
3.2.1 Market Status by Types in China
3.2.2 Market Status by Types in Japan
3.2.3 Market Status by Types in Korea
3.2.4 Market Status by Types in India
3.2.5 Market Status by Types in Southeast Asia
3.2.6 Market Status by Types in Australia
3.3 Market Forecast of Neisseria meningitidis Infections Drug in Asia Pacific by Types
CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Neisseria meningitidis Infections Drug in Asia Pacific by Downstream Industry
4.2 Demand Volume of Neisseria meningitidis Infections Drug by Downstream Industry in Major Countries
4.2.1 Demand Volume of Neisseria meningitidis Infections Drug by Downstream Industry in China
4.2.2 Demand Volume of Neisseria meningitidis Infections Drug by Downstream Industry in Japan
4.2.3 Demand Volume of Neisseria meningitidis Infections Drug by Downstream Industry in Korea
4.2.4 Demand Volume of Neisseria meningitidis Infections Drug by Downstream Industry in India
4.2.5 Demand Volume of Neisseria meningitidis Infections Drug by Downstream Industry in Southeast Asia
4.2.6 Demand Volume of Neisseria meningitidis Infections Drug by Downstream Industry in Australia
4.3 Market Forecast of Neisseria meningitidis Infections Drug in Asia Pacific by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF NEISSERIA MENINGITIDIS INFECTIONS DRUG
5.1 Asia Pacific Economy Situation and Trend Overview
5.2 Neisseria meningitidis Infections Drug Downstream Industry Situation and Trend Overview
CHAPTER 6 NEISSERIA MENINGITIDIS INFECTIONS DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC
6.1 Sales Volume of Neisseria meningitidis Infections Drug in Asia Pacific by Major Players
6.2 Revenue of Neisseria meningitidis Infections Drug in Asia Pacific by Major Players
6.3 Basic Information of Neisseria meningitidis Infections Drug by Major Players
6.3.1 Headquarters Location and Established Time of Neisseria meningitidis Infections Drug Major Players
6.3.2 Employees and Revenue Level of Neisseria meningitidis Infections Drug Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 NEISSERIA MENINGITIDIS INFECTIONS DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Beijing Minhai Biotechnology Co Ltd
7.1.1 Company profile
7.1.2 Representative Neisseria meningitidis Infections Drug Product
7.1.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of Beijing Minhai Biotechnology Co Ltd
7.2 Biological E Ltd
7.2.1 Company profile
7.2.2 Representative Neisseria meningitidis Infections Drug Product
7.2.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of Biological E Ltd
7.3 China National Pharmaceutical Group Corp
7.3.1 Company profile
7.3.2 Representative Neisseria meningitidis Infections Drug Product
7.3.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of China National Pharmaceutical Group Corp
7.4 GlaxoSmithKline Plc
7.4.1 Company profile
7.4.2 Representative Neisseria meningitidis Infections Drug Product
7.4.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of GlaxoSmithKline Plc
7.5 Griffith University
7.5.1 Company profile
7.5.2 Representative Neisseria meningitidis Infections Drug Product
7.5.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of Griffith University
7.6 ImmunoBiology Ltd
7.6.1 Company profile
7.6.2 Representative Neisseria meningitidis Infections Drug Product
7.6.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of ImmunoBiology Ltd
7.7 JN-International Medical Corp
7.7.1 Company profile
7.7.2 Representative Neisseria meningitidis Infections Drug Product
7.7.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of JN-International Medical Corp
7.8 MGB Biopharma Ltd
7.8.1 Company profile
7.8.2 Representative Neisseria meningitidis Infections Drug Product
7.8.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of MGB Biopharma Ltd
7.9 Panacea Biotec Ltd
7.9.1 Company profile
7.9.2 Representative Neisseria meningitidis Infections Drug Product
7.9.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of Panacea Biotec Ltd
7.10 Pfizer Inc
7.10.1 Company profile
7.10.2 Representative Neisseria meningitidis Infections Drug Product
7.10.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of Pfizer Inc
7.11 Sanofi Pasteur SA
7.11.1 Company profile
7.11.2 Representative Neisseria meningitidis Infections Drug Product
7.11.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of Sanofi Pasteur SA
7.12 Serum Institute of India Ltd
7.12.1 Company profile
7.12.2 Representative Neisseria meningitidis Infections Drug Product
7.12.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of Serum Institute of India Ltd
7.13 Wellstat Vaccines LLC
7.13.1 Company profile
7.13.2 Representative Neisseria meningitidis Infections Drug Product
7.13.3 Neisseria meningitidis Infections Drug Sales, Revenue, Price and Gross Margin of Wellstat Vaccines LLC
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NEISSERIA MENINGITIDIS INFECTIONS DRUG
8.1 Industry Chain of Neisseria meningitidis Infections Drug
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF NEISSERIA MENINGITIDIS INFECTIONS DRUG
9.1 Cost Structure Analysis of Neisseria meningitidis Infections Drug
9.2 Raw Materials Cost Analysis of Neisseria meningitidis Infections Drug
9.3 Labor Cost Analysis of Neisseria meningitidis Infections Drug
9.4 Manufacturing Expenses Analysis of Neisseria meningitidis Infections Drug
CHAPTER 10 MARKETING STATUS ANALYSIS OF NEISSERIA MENINGITIDIS INFECTIONS DRUG
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
